YOLFTbeta
Medprin Regenerative Medical Technologies Co. Ltd.

Medprin Regenerative Medical Technologies Co. Ltd.

301033 · SHE · Healthcare / Medical Devices

49.78CNY-1.62 (-3.15%)

Price History

Full chart

Market Stats

Previous Close51.40
Open51.61
Day Range49.75 – 51.61
52-Week Range44.88 – 90.71
Volume946.71K
Market Cap3.63B
P/E (TTM)29.48
Forward P/E0.00
EPS1.82
Dividend Yield1.30%
Beta-0.05
50-Day Avg56.09
200-Day Avg60.46

About

Medprin Regenerative Medical Technologies Co., Ltd. engages in the research and development, manufacture, and sale of implantable medical devices in China and internationally. The company offers artificial dura mater patches, craniofacial repair and fixation systems, and absorbable regenerative oxidation for neurosurgery meningeal repair, skull repair fixation and rapid hemostasis, etc. It also offers ReDura, a Synthetic Dural Substitute; NeoDura, a novel dural patch; Recranio, a Cranio-Maxillofacial repair system; and StypCel, an Absorbable Hemostat; Immiseal, a dural sealant system; and 3D bioprinting applications serving patients internationally. Medprin Regenerative Medical Technologies Co., Ltd. was founded in 2008 and is headquartered in Guangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Jianhua Wang
  • Employees447
  • HeadquartersNo. 3 Yayingshi Road, Guangzhou, China, 510700, China
  • Websitehttps://www.medprin.com

Leadership

  • Mr. Jianhua WangGM & Director · b. 1968
  • Ms. Yahong LuoCFO, Deputy GM & Non-Independent Director · b. 1968
  • Ms. Xiaoyan LongDeputy GM, Board Secretary & Non-Independent Director · b. 1984
  • Ms. Yuanyuan LiDeputy General Manager · b. 1982
  • Zhiguo SunAccounting Supervisor

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue113.24M123.51M153.79M195.25M230.87M278.44M368.83M
Growth (%)-+9.07%+24.51%+26.96%+18.24%+20.61%+32.46%
Cost of Revenue16.34M20.40M27.09M31.23M41.54M57.56M72.92M
Gross Profit96.90M103.11M126.70M164.02M189.33M220.88M295.91M
Gross Margin85.57%83.48%82.39%84.01%82.01%79.33%80.23%
Operating Expense71.80M68.25M89.21M130.89M144.15M133.90M168.97M
Operating Income25.10M34.86M37.48M33.14M45.18M86.98M126.94M
Operating Margin22.17%28.22%24.37%16.97%19.57%31.24%34.42%
EBITDA36.23M40.35M60.28M56.91M75.56M121.19M153.69M
EBITDA Margin31.99%32.67%39.20%29.14%32.73%43.52%41.67%
Net Income27.68M36.97M44.71M35.89M40.88M78.85M113.13M
Net Income Margin24.44%29.93%29.08%18.38%17.71%28.32%30.67%
R&D18.21M16.28M25.88M30.61M26.78M27.09M36.96M
R&D as % of Total Revenue16.08%13.18%16.83%15.68%11.60%9.73%10.02%
Interest Expense--494.52K1.78M2.21M904.08K19.72K
Interest Expense % of Total Revenue--0.32%0.91%0.96%0.32%0.01%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets340.05M455.34M746.78M744.92M786.97M799.23M895.44M
Total Liabilities37.27M117.26M170.92M142.34M151.11M99.57M97.38M
Total Equity299.03M334.43M572.26M602.58M635.86M699.66M798.06M
Cash28.39M11.69M10.35M44.96M26.68M57.45M74.02M
Net Debt-35.81M91.32M5.34M19.75M--

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow31.27M33.91M66.51M48.31M107.69M116.38M139.87M
Capital Expenditure36.71M61.65M152.71M135.96M40.09M33.16M23.82M
Free Cash Flow-5.44M-27.74M-86.20M-87.65M67.60M83.22M116.05M
Dividends Paid---8.05M15.28M27.14M39.70M
FCF to OCF-17.38%-81.80%-129.60%-181.43%62.77%71.51%82.97%
Dividend Paid to FCF----9.19%22.60%32.61%34.21%

Earnings

Report DateSep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Aug 18, 2024Oct 28, 2024Dec 31, 2024Apr 25, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------
EPS Actual0.170.190.110.210.130.090.120.060.200.230.230.270.310.390.370.350.430.550.310.54
Surprise--------------------
Timing-----------Pre-marketPre-market-After-hours-----

Key Statistics & Ratios

Market Cap3.63B
Enterprise Value3.48B
Trailing P/E29.48
Forward P/E0.00
Price / Sales9.05
Price / Book4.63
EPS1.82
Book Value12.15
Revenue (TTM)400.85M
Gross Profit (TTM)315.04M
EBITDA153.40M
Profit Margin30.54%
Operating Margin36.83%
Return on Equity16.02%
Return on Assets9.34%
Shares Outstanding67.63M
Shares Float34.67M
Beta-0.05
Dividend Yield1.30%
Dividend Rate0.70
Payout Ratio38.30%

Dividends

20261×
0.70Jun 1, 2026
20251×
0.60May 30, 2025
20241×
0.40Jun 26, 2024
20231×
0.20Jun 1, 2023
20221×
0.10Jun 1, 2022